ATE303131T1 - Zusammensetzungen zur nasalen verabreichung - Google Patents

Zusammensetzungen zur nasalen verabreichung

Info

Publication number
ATE303131T1
ATE303131T1 AT98955814T AT98955814T ATE303131T1 AT E303131 T1 ATE303131 T1 AT E303131T1 AT 98955814 T AT98955814 T AT 98955814T AT 98955814 T AT98955814 T AT 98955814T AT E303131 T1 ATE303131 T1 AT E303131T1
Authority
AT
Austria
Prior art keywords
compositions
nasal administration
nasal
administration
Prior art date
Application number
AT98955814T
Other languages
English (en)
Inventor
Lisbeth Illum
Peter James Watts
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9725519.4A external-priority patent/GB9725519D0/en
Priority claimed from GBGB9805253.3A external-priority patent/GB9805253D0/en
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Application granted granted Critical
Publication of ATE303131T1 publication Critical patent/ATE303131T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98955814T 1997-12-02 1998-11-27 Zusammensetzungen zur nasalen verabreichung ATE303131T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9725519.4A GB9725519D0 (en) 1997-12-02 1997-12-02 Nasal formulation
GBGB9805253.3A GB9805253D0 (en) 1998-03-13 1998-03-13 Nasal formulation
PCT/GB1998/003572 WO1999027905A1 (en) 1997-12-02 1998-11-27 Compositions for nasal administration

Publications (1)

Publication Number Publication Date
ATE303131T1 true ATE303131T1 (de) 2005-09-15

Family

ID=26312701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955814T ATE303131T1 (de) 1997-12-02 1998-11-27 Zusammensetzungen zur nasalen verabreichung

Country Status (13)

Country Link
US (2) US6342251B1 (de)
EP (1) EP1035833B1 (de)
JP (2) JP4754067B2 (de)
AR (1) AR017694A1 (de)
AT (1) ATE303131T1 (de)
AU (1) AU751182B2 (de)
CA (1) CA2312839C (de)
DE (1) DE69831421T2 (de)
DK (1) DK1035833T3 (de)
ES (1) ES2249846T3 (de)
NO (1) NO329381B1 (de)
NZ (1) NZ504786A (de)
WO (1) WO1999027905A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
KR20020015310A (ko) * 1999-04-06 2002-02-27 로버트 엘. 로브 신체적인 성적반응을 변화시키는 방법
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6632419B2 (en) * 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
CN1471395A (zh) 2000-04-07 2004-01-28 ����ҽҩƷ���޹�˾ 阿扑吗啡衍生物及其使用方法
US6565851B2 (en) * 2000-05-26 2003-05-20 Horphag Research Limited Relieving symptoms of erectile dysfunction with proanthocyanidins
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
ES2295391T3 (es) 2001-08-16 2008-04-16 Cmp Therapeutics Limited Microparticulas de quitina y sus usos medicos.
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
AU2003234090A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
AU2003230908A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
JP2006522785A (ja) * 2003-04-14 2006-10-05 ベクトゥラ・リミテッド アポモルヒネを含む肺吸入用医薬組成物
CA2523870A1 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US8846102B2 (en) * 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
US8771711B2 (en) 2006-04-21 2014-07-08 Toko Yakuhin Kogyo Kabushiki Kaisha Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US7976873B2 (en) * 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
WO2009040595A1 (en) * 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
EP2057982A1 (de) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasale Zusammensetzungen
CN102883715B (zh) 2008-04-24 2014-11-12 麦德托尼克公司 包含壳聚糖的保护性组合物
AU2009240512B2 (en) 2008-04-24 2014-07-10 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
US9198997B2 (en) 2008-04-24 2015-12-01 Medtronic, Inc. Rehydratable thiolated polysaccharide particles and sponge
US8653319B2 (en) 2008-04-24 2014-02-18 Medtronic, Inc. Cold ionizing radiation sterilization
EP2303254B1 (de) 2008-06-12 2019-10-30 Medtronic Xomed, Inc. Produkt zur behandlung von chronischen wunden mit einem extrazellulären polymer-substanz-solvatisierungssystem
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2346324A4 (de) * 2008-10-06 2012-10-10 Microbial Defense Systems Llc Antimikrobielle zusammensetzung sowie verfahren zu ihrer herstellung und verwendung
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
BR112013028673B1 (pt) 2011-05-10 2020-06-16 Next Science IP Holdings Pty Ltd Sólido antimicrobiano e métodos de fazer e usar o mesmo
CN105579057A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
MX2017006655A (es) * 2014-11-20 2018-03-12 Allergan Inc Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico.
EP3056219B1 (de) * 2015-02-12 2018-08-22 Laboratoires Chemineau Zusammensetzung auf pflanzenbasis der familie der malvengewächse (malvaceae) zur verabreichung auf schleimhäuten
FR3032618A1 (fr) * 2015-02-12 2016-08-19 Laboratoires Chemineau Composition a base de plantes de la famille des malvaceae pour une administration dans la cavite nasale
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US12569493B2 (en) 2020-03-24 2026-03-10 Cyrano Therapeutics Inc. Treatment of chemosensory dysfunction from a coronavirus infection
JP2025502075A (ja) * 2022-01-06 2025-01-24 シラノ セラピューティクス， インコーポレイテッド パーキンソン病治療剤の改善された鼻投与

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62123112A (ja) 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
DE3601132A1 (de) 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
JPS62236862A (ja) 1986-04-09 1987-10-16 Nippon Kayaku Co Ltd 人工粘液
WO1988004926A1 (en) * 1987-01-08 1988-07-14 Nastech Pharmaceutical Company, Inc. Nasal delivery of amino acids
US4826683A (en) * 1987-01-09 1989-05-02 Bates Harry L Decongestant
FR2614021B1 (fr) * 1987-04-14 1991-03-01 Andre Buzas Derives de la 1-((1,1-diphenyl)-1-alcenyl)-piperazine, procede d'obtention et compositions pharmaceutiques les contenant
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
DE3827561C1 (de) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
JPH0436233A (ja) * 1990-05-29 1992-02-06 Biomaterial Universe Kk 生理活性物質含有生体内分解吸収性の徐放性製剤
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
DE69429768T2 (de) * 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
BR9407397A (pt) * 1993-07-12 1996-11-05 Virus Res Inst Vacinas microencapsuladas em hidrogel
JP3696265B2 (ja) * 1994-02-04 2005-09-14 日本オルガノン株式会社 点鼻液剤
ES2143049T3 (es) * 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces

Also Published As

Publication number Publication date
AU1253599A (en) 1999-06-16
DK1035833T3 (da) 2006-01-09
ES2249846T3 (es) 2006-04-01
WO1999027905A1 (en) 1999-06-10
JP2001524509A (ja) 2001-12-04
AU751182B2 (en) 2002-08-08
NZ504786A (en) 2005-07-29
US6342251B1 (en) 2002-01-29
AR017694A1 (es) 2001-09-12
EP1035833A1 (de) 2000-09-20
CA2312839C (en) 2008-01-15
DE69831421D1 (de) 2005-10-06
NO20002851D0 (no) 2000-06-02
US20010046519A1 (en) 2001-11-29
CA2312839A1 (en) 1999-06-10
JP2011026341A (ja) 2011-02-10
DE69831421T2 (de) 2006-06-22
NO329381B1 (no) 2010-10-04
EP1035833B1 (de) 2005-08-31
JP4754067B2 (ja) 2011-08-24
NO20002851L (no) 2000-06-02

Similar Documents

Publication Publication Date Title
DE69831421D1 (de) Zusammensetzungen zur nasalen verabreichung
NO20005913L (no) Legemiddelsammensetning
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID27415A (id) Komposisi farmaseutik
DE69738333D1 (de) Nichtpolare Spray zur bukkalen Verabreichung
IS5046A (is) Lyfjasamsetningar
DE69826299D1 (de) Inhalationsgerät
IS2703B (is) Innöndunartæki
DK0920302T3 (da) Farmaceutisk aerosolsammensætning
ID18352A (id) Komposisi-komposisi farmasi
ID29262A (id) Komposisi farmasi
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
DE69816736D1 (de) Nasale Inhaliervorrichtung
ID27201A (id) Komposisi farmasi
FR2763507B1 (fr) Inhalateur
IS5184A (is) Lyfjasamsetningar
DE69827947D1 (de) Rapamycin-formulierungen zur oralen verabreichung
EE200000330A (et) Farmatseutilised kompositsioonid
DE69824327D1 (de) Inhalationsgerät
PT941100E (pt) Composicoes farmaceuticas
ID26215A (id) Komposisi farmasi
NO994436D0 (no) Farmasöytiske sammensetninger
BR1100755A (pt) composição farmacêutica
BR1101089A (pt) Composição terapêutica de uso nasal
SE9400371D0 (sv) Compositions for inhalation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1035833

Country of ref document: EP